Axon degeneration in diabetic peripheral neuropathy (DPN) is associated with impaired NAD+ metabolism. We tested whether the administration of NAD+ precursors, nicotinamide mononucleotide (NMN) or nicotinamide riboside (NR), prevents DPN in models of Type 1 and Type 2 diabetes. NMN was administered to streptozotocin (STZ)-induced diabetic rats and STZ-induced diabetic mice by intraperitoneal injection at 50 or 100 mg/kg on alternate days for 2 months. mice The were fed with a high fat diet (HFD) for 2 months with or without added NR at 150 or 300 mg/kg for 2 months. The administration of NMN to STZ-induced diabetic rats or mice or dietary addition of NR to HFD-fed mice improved sensory function, normalized sciatic and tail nerve conduction velocities, and prevented loss of intraepidermal nerve fibers in skin samples from the hind-paw. In adult dorsal root ganglion (DRG) neurons isolated from HFD-fed mice, there was a decrease in NAD+ levels and mitochondrial maximum reserve capacity. These impairments were normalized in isolated DRG neurons from NR-treated mice. The results indicate that the correction of NAD+ depletion in DRG may be sufficient to prevent DPN but does not significantly affect glucose tolerance, insulin levels, or insulin resistance.
Background: Hyperkinetic movement disorders involve excessive, involuntary movements such as ataxia, chorea, dystonia, myoclonus, tics, and tremor. Recent advances in artificial intelligence (AI) allow investigators to integrate multimodal instrumented movement measurements and imaging techniques and to analyze these data together at scale. In this systematic review, we aim to characterize AI’s performance in diagnosing and quantitatively phenotyping these disorders. Methods: We searched PubMed and Embase using a semi-automated article-screening pipeline. Results: Fifty-five studies met the inclusion criteria (n = 11,946 subjects). Thirty-five studies used machine learning, sixteen used deep learning, and four used both. Thirty-eight studies reported disease diagnosis, twenty-three reported quantitative phenotyping, and six reported both. Diagnostic accuracy was reported in 36 of 38 and correlation coefficients in 10 of 23 studies. Kinematics (e.g., accelerometers and inertial measurement units) were the most used dataset. Diagnostic accuracy was reported in 36 studies and ranged from 56 to 100% compared to clinical diagnoses to differentiate them from healthy controls. The correlation coefficient was reported in 10 studies and ranged from 0.54 to 0.99 compared to clinical ratings for quantitative phenotyping. Five studies had an overall judgment of “low risk of bias” and three had external validation. Conclusion: There is a need to adopt AI-based research guidelines to minimize reporting heterogeneity and bolster clinical interpretability.
Abnormal NAD+ signaling has been implicated in axonal degeneration in diabetic peripheral neuropathy (DPN). We hypothesized that supplementing NAD+ precursors could alleviate DPN symptoms through increasing the NAD+ levels and activating the sirtuin-1 (SIRT1) protein. To test this, we exposed cultured Dorsal Root Ganglion neurons (DRGs) to Nicotinamide Riboside (NR) or Nicotinamide Mononucleotide (NMN), which increased the levels of NAD+, the SIRT1 protein, and the deacetylation activity that is associated with increased neurite growth. A SIRT1 inhibitor blocked the neurite growth induced via NR or NMN. We then induced neuropathy in C57BL6 mice with streptozotocin (STZ) or a high fat diet (HFD) and administered NR or NMN for two months. Both the STZ and HFD mice developed neuropathy, which was reversed through the NR or NMN administration: sensory function improved, nerve conduction velocities normalized, and intraepidermal nerve fibers were restored. The NAD+ levels and SIRT1 activity were reduced in the DRGs from diabetic mice but were preserved with the NR or NMN treatment. We also tested the effect of NR or NMN administration in mice that overexpress the SIRT1 protein in neurons (nSIRT1 OE) and found no additional benefit from the addition of the drug. These findings suggest that supplementing with NAD+ precursors or activating SIRT1 may be a promising treatment for DPN.
Background: Dystonia is characterized by involuntary intermittent or sustained abnormal movements or postures. Deep brain stimulation (DBS) is an effective treatment, and response has been shown to vary across body regions but literature depicting this pattern is conflicting. Our study analyzes dystonia response to DBS by body distribution using the Burke-Fahn-Marsden Rating Scale motor (BFMRS-M) score and the Global Dystonia Rating Scale (GDRS). Methods: We reviewed standardized videos of patients with isolated non-acquired dystonia obtained at baseline and post-DBS of unilateral or bilateral globus pallidus interna between 2008 and 2020. BFMRS-M and GDRS were scored using blinded assessment by two movement disorders neurologists. Mean baseline and post-DBS scores were compared using a paired t-test. Results: Ten male and 10 female patients were included, with average age at surgery 49 years. Post-DBS total BFMRS-M scores demonstrated improvement (20.5 ± 3.6 vs 11.9 ± 2.6) and there was significant improvement in neck sub-scores (4.9 ± 0.6 vs 2.5 ± 0.4). All patients demonstrated an improved total GDRS score post-DBS (21.6 ± 3.7 vs 11.1 ± 2.1), with significant improvements in GDRS sub-scores of the neck (5.9 ± 0.6 vs 2.6 ± 0.4) and shoulder & proximal arms (4.7 ± 1.1 vs 1.6 ± 0.5). Discussion: Efficacy of DBS varies by distribution of dystonia and should be considered in treatment planning discussions. GDRS is a more sensitive outcome measurement for dystonia compared to BFMRS-M and should be more routinely integrated into studying treatment response. Highlights This study shows that pallidal deep brain stimulation yields differential improvement across dystonia body regions, with greatest benefit in the neck and proximal arms. These results highlight that the Global Dystonia Rating Scale is more sensitive to regional outcomes compared to the commonly utilized Burke-Fahn-Marsden Rating Scale.
25 August 2026 in Parkinsonism & Related Disorders